Our Business Development team has expertise in biomedical science, technology transfer, business development, intellectual property, commercial negotiation and contracts. They work closely with our researchers to identify and develop laboratory discoveries that have the potential to translate from the research bench to the patient bedside.
The team manages a growing portfolio of both patented and undisclosed intellectual property. Our royalty generating licence agreements include a screening test for Down’s syndrome and a range of antibodies. There is also an exclusive licence agreement with Paranta Biosciences to develop and commercialise a potentially transformative technology developed at the Hudson Institute relating to the use of follistatin as a novel chemotherapy sensitising agent for patients with solid tissue cancers. In addition, the team have several research collaboration and licensing agreements in place that are subject to confidentiality restrictions.
Hudson Institute offers industry the opportunity to license our intellectual property, engage in collaborative research and development projects or provide contract research, accessing world-leading expertise and facilities.
The Hudson Institute is looking to increase its engagement with the biotechnology sector and venture capital investors. We have an exciting portfolio of discovery and pre-clinical technologies ready for commercial partnerships.